Nanoformulation-based medicines for the treatment of reactive oxygen species-induced diseases: A review

Abstract

Reactive oxygen species (ROS), are highly reactive molecules formed as a natural by-product during cellular metabolism primarily within the mitochondrial matrix. Excessive production of ROS may cause serious illnesses like cardiovascular disease, diabetes, cancer, Alzheimer's and Parkinson's disease. The therapeutic drugs currently available in the market for the treatment of these illnesses have larger systemic effects and a variety of adverse effects. Therefore, it is important to identify an alternative way of delivering drugs in the form of nanomedicine, which has low cost, great efficacy, fewer side effects, and narrower systemic effects. Nanoparticles have the potential to deliver drugs at specific targeted sites and can be used as new therapy methods for the treatment of various diseases and can also be used in diagnostic methods. This review paper aims to examine the synthesis of nanomedicine, its delivery methods within the body and its mechanism of action against ROS-induced diseases. The findings of our study suggest that nanomedicine-based therapy may be a very effective method in the treatment of cancer, diabetes mellitus, cardiovascular diseases, Alzheimer's and Parkinson's disease. However, nanomedicine raises a variety of safety concerns, including the risk of toxicity and persistence in the tissues of humans.